(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Revolution Medicines's earnings in 2026 is -$1,371,701,000.On average, 23 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,637,566,768, with the lowest RVMD earnings forecast at -$1,745,927,185, and the highest RVMD earnings forecast at -$1,381,770,705. On average, 21 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,293,373,096, with the lowest RVMD earnings forecast at -$1,737,593,403, and the highest RVMD earnings forecast at -$343,768,479.
In 2028, RVMD is forecast to generate -$868,371,509 in earnings, with the lowest earnings forecast at -$1,685,507,270 and the highest earnings forecast at $151,793,874.